- David M. Reese will retire effective June 30, 2026.
- Organizational changes effective June 1, 2026: James Bradner named EVP, Research and Development, Artificial Intelligence and Data.
- Sean Bruich appointed senior vice president and Chief Technology Officer; Murdo Gordon named executive vice president, Global Markets and Policy.
- Paul Burton will continue as senior vice president and Chief Medical Officer.
Retirement
David M. Reese will retire as executive vice president and Chief Technology Officer effective June 30, 2026.
Background and contributions
Reese joined Amgen in 2005 and served as EVP of Research and Development from 2018–2023; he led approvals of multiple medicines and biosimilars, advanced the pipeline, strengthened discovery research, and as inaugural CTO promoted early adoption of technology and AI across the business, particularly in R&D.
Leadership changes
Effective June 1, 2026, James Bradner will serve as EVP, Research and Development, Artificial Intelligence and Data; Sean Bruich will be senior vice president and Chief Technology Officer; Murdo Gordon will be EVP, Amgen Global Markets and Policy (including Medical, Commercial Operations, Government Affairs and Policy); Paul Burton will continue as senior vice president and Chief Medical Officer.
Strategic intent
The reorganization is intended to deepen integration of biology, data science and advanced technologies—“convergent innovation”—to accelerate discovery and development and better align the company with evolving technology adoption across the health-care ecosystem.
